Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial

  • Tali Cukierman-Yaffe
  • , Hertzel C. Gerstein*
  • , Jan Basile
  • , M. Angelyn Bethel
  • , Ernesto G. Cardona-Munoz
  • , Ignacio Conget
  • , Gilles Dagenais
  • , Edward Franek
  • , Stephanie Hall
  • , Nicolae Hancu
  • , Petr Jansky
  • , Mark Lakshmanan
  • , Fernando Lanas
  • , Lawrence A. Leiter
  • , Patricio Lopez-Jaramillo
  • , Valdis Pīrāgs
  • , Nana Pogosova
  • , Jeffrey Probstfield
  • , Purnima Rao-Melacini
  • , Chinthanie Ramasundarahettige
  • Peter J. Raubenheimer, Matthew C. Riddle, Lars Ryden, Jonathan E. Shaw, H. H. Sheu, Theodora Temelkova-Kurktschiev
*Šī darba korespondējošais autors
    • Tel Aviv University
    • Hamilton Health Sciences
    • Medical University of South Carolina
    • Eli Lilly
    • Universidad de Guadalajara
    • Hospital Clinic de Barcelona
    • Université Laval
    • Mossakowski Medical Research Centre Polish Academy of Science
    • Iuliu Hatieganu University of Medicine and Pharmacy
    • Charles University
    • Universidad de la Frontera
    • University of Toronto
    • Universidad de Santander
    • Paula Stradina Clinical University Hospital
    • RAS - USSR Cardiology Research Center
    • University of Washington
    • University of Cape Town
    • Oregon Health and Science University
    • Karolinska Institutet
    • Baker Heart Research Institute
    • Veterans General Hospital-Taichung Taiwan
    • Robert Koch Medical Centre

    Zinātniskās darbības rezultāts: Devums žurnālamZinātniskais raksts (žurnālā)koleģiāli recenzēts

    3 Atsauces (Scopus)

    Kopsavilkums

    Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationship is stronger using novel cognitive indices is unknown. Methods: Participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial who completed both the Montreal Cognitive Assessment (MoCA) score and Digit Substitution Test (DSST) at baseline (N = 8772) were included. These scores were used to identify participants with baseline substantive cognitive impairment (SCI), defined as a baseline score on either the MoCA or DSST ≥ 1.5 SD below either score's country-specific mean, or SCI-GM, which was based on a composite index of both scores calculated as their geometric mean (GM), and defined as a score that was ≥ 1.5 SD below their country's average GM. Relationships between these measures and incident major adverse cardiovascular events (MACE), and either stroke or death were analyzed. Results: Compared with 7867 (89.7%) unaffected participants, the 905 (10.3%) participants with baseline SCI had a higher incidence of MACE (unadjusted hazard ratio [HR] 1.34; 95% CI 1.11, 1.62; P = 0.003), and stroke or death (unadjusted HR 1.60; 95% CI 1.33, 1.91; P < 0.001). Stronger relationships were noted for SCI-GM and MACE (unadjusted HR 1.61; 95% CI 1.28, 2.01; P < 0.001), and stroke or death (unadjusted HR 1.85; 95% CI 1.50, 2.30; P < 0.001). For SCI-GM but not SCI, all these relationships remained significant in models that adjusted for up to 10 SCI risk factors. Conclusion: Country-standardized SCI-GM was a strong independent predictor of cardiovascular events in people with type 2 diabetes in the REWIND trial.

    OriģinālvalodaAngļu
    Lapas (no-līdz)E3448-E3454
    ŽurnālsJournal of Clinical Endocrinology and Metabolism
    Sējums107
    Izdevuma numurs8
    DOIs
    Publikācijas statussPublicēts - 1 aug. 2022

    ANO IAM

    Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

    1. 3. IAM — Laba Veselība un Labbūtība
      3. IAM — Laba Veselība un Labbūtība

    OECD Zinātnes nozare

    • 3. Medicīnas un veselības zinātnes

    Nospiedums

    Uzziniet vairāk par pētniecības tēmām “Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial”. Kopā tie veido unikālu nospiedumu.

    Citēt šo